Protection of mitochondria prevents high-fat diet–induced glomerulopathy and proximal tubular injury

• DOI: 10.1016/j.kint.2016.06.013
• Publication Date: 2016-08-09T20:59:26Z
• Authors: Hazel H. Szeto; Shaoyi Liu; Yi Soong; Nazia Alam; Glen T. Prusky; Surya V. Seshan
• Keywords: Blood Glucose; 0301 basic medicine; 2. Zero hunger; Podocytes; Body Weight; Drug Evaluation, Preclinical; Apoptosis; AMP-Activated Protein Kinases; Diet, High-Fat; Endoplasmic Reticulum Stress; Lipid Metabolism; Capillaries; Mitochondria; 3. Good health; Kidney Tubules, Proximal; Mice, Inbred C57BL; 03 medical and health sciences; Glomerulonephritis; Microscopy, Electron, Transmission; Animals; Endothelium, Vascular; Obesity; Oligopeptides

Obesity is a major risk factor for the development of chronic kidney disease, even independent of its association with hypertension, diabetes, and dyslipidemia. The primary pathologic finding of obesity-related kidney disease is glomerulopathy, with glomerular hypertrophy, mesangial matrix expansion, and focal segmental glomerulosclerosis. Proposed mechanisms leading to renal pathology include abnormal lipid metabolism, lipotoxicity, inhibition of AMP kinase, and endoplasmic reticulum stress. Here we report dramatic changes in mitochondrial structure in glomerular endothelial cells, podocytes, and proximal tubular epithelial cells after 28 weeks of a high-fat diet in C57BL/6 mice. Treatment with SS-31, a tetrapeptide that targets cardiolipin and protects mitochondrial cristae structure, during high-fat diet preserved normal mitochondrial structure in all kidney cells, restored renal AMP kinase activity, and prevented intracellular lipid accumulation, endoplasmic reticulum stress, and apoptosis. SS-31 had no effect on weight gain, insulin resistance or hyperglycemia. However, SS-31 prevented loss of glomerular endothelial cells and podocytes, mesangial expansion, glomerulosclerosis, macrophage infiltration, and upregulation of proinflammatory (TNF-α, MCP-1, NF-κB) and profibrotic (TGF-β) cytokines. Thus, mitochondria protection can overcome lipotoxicity in the kidney and represent a novel upstream target for therapeutic development.